Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

Core Viewpoint - Corvus Pharmaceuticals has announced the approval of an IND application for a Phase 1b/2 clinical trial of soquelitinib in China, targeting patients with moderate-to-severe atopic dermatitis, which is expected to begin patient enrollment in Q3 2025 [1][3]. Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a new immunotherapy approach for various cancers and immune diseases [6][7]. - Angel Pharmaceuticals, co-founded by Corvus, is responsible for developing, manufacturing, and commercializing soquelitinib in greater China, with Corvus holding approximately 49.7% ownership [2][5]. Clinical Trial Details - The Phase 1b/2 trial will study a 12-week treatment period with a 400 mg once-daily dose of soquelitinib, building on previous clinical data [3][6]. - The trial will be randomized, double-blinded, and placebo-controlled, enrolling patients with moderate-to-severe atopic dermatitis [3][6]. - The Phase 1b trial will include two cohorts, each with 24 patients, testing different dosing regimens [6]. Market Context - Atopic dermatitis is a growing concern globally, with increasing use of biologics and systemic therapies, particularly in China [3].